UNIVERSITY OF GEORGIA

Bioxytran's antiviral compound PHM23 has been selected by the University of Georgia for inclusion in their grant submission to the USDA's $100 million Highly Pathogenic Avian Influenza Poultry Innovation Grand Challenge.

Updated 2024 RSV vaccination guidelines now strongly recommend vaccination for adults 75 and older, while those 60-74 with risk factors should receive the shot, replacing previous shared decision-making approach.

Blue Lake Biotechnology's experimental nasal COVID-19 vaccine demonstrated 86% efficacy in reducing symptomatic infections for three months in Phase 1 trials, significantly outperforming existing mRNA boosters.